Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 160, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103308
Keywords
KRAS; Prognostic biomarkers; Colorectal cancer; Lung metastasis; Metastasectomy
Categories
Funding
- National Natural Science Foundation of China [81572424/82072620]
- Guangdong Basic and Applied Basic Research Foundation [2020A1515110056]
Ask authors/readers for more resources
This study found that KRAS mutation is associated with worse overall survival and recurrence free survival in colorectal cancer patients undergoing pulmonary metastasectomy, along with 18 other factors showing significant effects. This supports the use of a comprehensive model including clinicopathological and biological factors for optimal patient selection and prognosis in surgical treatment.
Background: The purpose of the study was to evaluate whether KRAS mutation could be an independent prognostic biomarker in patients undergoing pulmonary metastasectomy (PM) for colorectal cancer (CRC). Methods: A systemic review was performed by searching online databases to identify studies reporting overall survival (OS) and recurrence free survival (RFS) of CRC patients undergoing PM. Pooled HRs were calculated for OS and RFS. Results: A total of 15233 patients from 60 studies were included. Pooled analysis showed that KRAS mutation was associated with worse OS (HR: 1.86, 95 % Cl: 1.35-2.57) and RFS (HR: 1.68, 95 % Cl: 1.38-2.04). A significant effect on OS and/or RFS was also shown by other 18 factors. Conclusions: This meta-analysis found that KRAS mutation is an important prognostic predictor for OS and RFS in CRC patients undergoing PM, supporting a comprehensive model including clinicopathological and biological factors for optimal patients selection and prognosis for surgical treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
